slide1
Download
Skip this Video
Download Presentation
Sarcoma Research Laboratory Houston, TX

Loading in 2 Seconds...

play fullscreen
1 / 18

Sarcoma Research Laboratory Houston, TX - PowerPoint PPT Presentation


  • 52 Views
  • Uploaded on

The desmoid tumor proteome: identifying molecular markers using a clinically annotated tissue microarray. Shohrae Hajibashi, Wei-Lien Wang, Alexander J.F. Lazar, Daniel Tuvin, Carla L. Warneke, Dolores Lopez-Terrada, Raphael E. Pollock, Dina Lev. Sarcoma Research Laboratory Houston, TX.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Sarcoma Research Laboratory Houston, TX' - nerita


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

The desmoid tumor proteome: identifying molecular markers using a clinically annotated tissue microarray

Shohrae Hajibashi, Wei-Lien Wang, Alexander J.F. Lazar, Daniel Tuvin, Carla L. Warneke, Dolores Lopez-Terrada, Raphael E. Pollock, Dina Lev

Sarcoma Research Laboratory

Houston, TX

unresolved clinical issues
Unresolved clinical issues
  • Lack of prognostic markers
  • Need for better therapeutics
bridging the biological gap
Bridging the biological gap
  • Impediments to progress:
    • Relative rarity
    • Limited collected human specimens
    • No cell lines
    • No animal models
  • Molecular determinants not well understood
slide4

UTMDACC desmoid tissue microarray (TMA)

  • Formalin-fixed, paraffin-embedded desmoid tumors (195 specimens from 160 patients; 1985-2005)
  • Clinical information including:
    • Demographic
    • Therapeutic
    • Clinical outcome
slide5

UTMDACC desmoid TMA

  • Automated TMA apparatus: 0.6-mm punch samples (2/case) formatted into three recipient blocks
  • 195 specimens: 110 primary/ 85 recurrent; 27 autologous pairs; 18 scars
  • H&E-staining of 4-µm TMA sections used to verify all samples
slide6

Clinical annotation

  • Gender: F 62%; M 38%
  • Median age: 32 yr old
  • Site
    • Superficial trunk 39%
    • Extremity 38%
    • Deep trunk/mesentery 13%
    • Head and neck 10%
  • Median size: 6 cm
  • FAP associated: 8%
slide8

Example: high -catenin TMA nuclear expression correlates with outcome

High, n=49

Low-moderate, n=40

p=0.0406

TMA: ~98% of the desmoids showed nuclear reactivity

slide9

Specific mutations in the -catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors

Am J Path. 173(5):1518-27; Nov 2008

47 (53%)

20 (22%)

15 (17%)

p=0.0002

next steps an algorithm for desmoid investigation
Next steps…an algorithm for desmoid investigation

1. “Up front” identification of potential desmoid-related/specific over-expressed genes

2. Confirm that gene over-expression leads to protein over production (TMA; different samples)

3. Validate these proteins as prognostic markers

4. Examine as possible targets for therapy

1 up front identification of potential desmoid related specific over expressed genes
1. “Up front” identification of potential desmoid-related/specific over-expressed genes

Human exonic evidence based oligonucleotide (HEEBOChip) microarray

10 desmoid tumor samples (20 additional specimens;

van de Rijn/West; Stanford)

1 up front identification of potential desmoid related specific over expressed genes1
1. “Up front” identification of potential desmoid-related/specific over-expressed genes
slide13

2. Confirm that gene over-expression leads to protein over production (TMA)

ADAM12

MDK

Scar

Desmoid

Scar

Desmoid

100% (+)

43% (+)

3 4 examine adam12 as a prognostic marker possible target for future desmoid therapy
3 & 4. Examine ADAM12 as a prognostic marker; possible target for (future) desmoid therapy?

ADAM12 protein: disintegrin

and metalloprotease; up-regulated in many human cancers

Role in tumor progression

ECM remodeling

resistance to apoptosis

prognostic marker:

breast/prostate cancers

3 4 examine adam12 as a prognostic marker possible target for future desmoid therapy1

ADAM12

Actin

3 & 4. Examine ADAM12 as a prognostic marker; possible target for (future) desmoid therapy?

ADAM12 over-expressed in desmoid cell cultures

NHF

Des 12

Des 2

Des 15

Anti-ADAM12 agents in pipe line…

conclusions and implications
Conclusions and implications:
  • Needed: comprehensive strategies to identify desmoid-related prognostic markers and therapeutic targets
  • High throughput gene/protein expression arrays for target identification: a potential approach
  • TMA studies: intense nuclear -catenin expression associates with less aggressive desmoid behavior
  • ADAM12: highly expressed in desmoids; currently being studied as a prognostic factor and therapeutic target
acknowledgements
Acknowledgements
  • The Sarcoma Research Laboratory
    • D. Lev, MD
    • R. Pollock, MD/PhD
    • A. Lazar, MD/PhD
    • Colleagues and staff
  • Stanford University Medical Center
    • M. van de Rijn, MD/PhD
    • R. West, MD/PhD
  • Desmoid Tumor Research Foundation
ad